Back to results
US 2024/0391995 A1Published application
Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
AssigneeInflaRx GmbH
InventorsNiels Christoph RIEDEMANN, Renfeng GUO
Life of this patent
Estimating the term…
Abstract
The present invention relates to an inhibitor of C5a activity and an inhibitor of IL-6 activity for use in the treatment of infectious pneumonia and infectious acute respiratory distress syndrome (ARDS). In further aspects administration regimes and kit of parts are referred to.
Claims6
A method of treating infectious pneumonia and/or infectious acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 infection, the method comprising:
- administering to a patient in need thereof an inhibitor of C5a activity
- (i) in combination with an inhibitor of IL-6 activity;
- and/or
- (ii) wherein the patient is or has been treated with an inhibitor of IL-6 activity;
- and
- wherein the inhibitor of C5a activity is vilobelimab and the inhibitor of IL-6 activity is tocilizumab.
3 more elements
-14. (canceled)
-30. (canceled)
Dependencies are inferred from the claim text.